L-NMMA Acetate

L-NMMA acetate is a nitric oxide synthase inhibitor of all NOS isoforms, like NOS1, NOS2, and NOS3.

Specification Technical Data Related Products Customer reviews and Q&A Useful Tools Publications

CAT#	10-101-117
CAS	17035-90-4 (net), 53308-83-1 (acetate)
Background	L-NMMA is the archetypal competitive NOS inhibitor to which other inhibitors are often compared. It is a relatively non-selective inhibitor of all NOS isoforms. The Ki values for nNOS (rat), eNOS (human), and iNOS (mouse) are approximately 0.18, 0.4, and 6 µM, respectively. >> Read More
Synonyms/Alias	Tilarginine Acetate; Targinine Acetate
M.F/Formula	C9H20N4O4
M.W/Mr.	248.28
Sequence	H-Arg(Me)-OH acetate salt
Labeling Target	Tilarginine
Application	L-NMMA is a useful clinical tool as NO synthase inhibitor to study the role and the effects of NO in cardiovascular and gastrointestinal disorders, hypertension, septic shock, inflammation, infection, stroke and neurodegenerative disorders.
Activity	Inhibitor
Areas of Interest	Cardiovascular Disease
Target	NO Synthase

CAT#	Product Name	M.W	Molecular Formula	Inquiry
10-101-113	Carbocysteine	179.19	C5H9NO4S	Inquiry
10-101-114	Darifenacin Hydrobromide	507.5	C28H31BrN2O	Inquiry
10-101-115	Deferasirox	373.3615	C21H15N3O4	Inquiry
10-101-13	Elcatonin Acetate	3363.8	C148H244N42O47	Inquiry
10-101-74	CCK-4 Acetate	596.71	C29H36N6O6S	Inquiry

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Source#	Synthetic
Long-term Storage Conditions	−20°C
InChI	InChI=1S/C7H16N4O2.C2H4O2/c1-10-7(9)11-4-2-3-5(8)6(12)13;1-2(3)4/h5H,2-4,8H2,1H3,(H,12,13)(H3,9,10,11);1H3,(H,3,4)/t5-;/m0./s1
InChI Key	IKPNWIGTWUZCKM-JEDNCBNOSA-N
Isomeric SMILES	CC(=O)O.CN=C(N)NCCC[C@@H](C(=O)O)N
References	Cardiogenic shock complicating acute myocardial infarction (MI) remains a common and lethal disorder despite aggressive use of early revascularization. Systemic inflammation, including expression of inducible nitric oxide synthase (NOS) and generation of excess nitric oxide, is believed to contribute to the pathogenesis and inappropriate vasodilatation of persistent cardiogenic shock. Preliminary, single-center studies suggested a beneficial effect of NOS inhibition on hemodynamics, renal function, and survival in patients with cardiogenic shock. Alexander, J. H., Reynolds, H. R., Stebbins, A. L., Dzavik, V., Harrington, R. A., Van de Werf, F., & Hochman, J. S. (2007). Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. Jama, 297(15), 1657-1666. Syncope is sudden transient loss of consciousness and postural tone with spontaneous recovery; the most common form is vasovagal syncope(VVS). We previously demonstrated impaired post-synaptic adrenergic responsiveness in young VVS patientswas reversed by blocking nitric oxide synthase(NOS). We hypothesised that nitric oxide may account for reduced orthostatic tolerance in young recurrent VVS patients. Stewart, J. M., Sutton, R., Kothari, M. L., Goetz, A. M., Visintainer, P., & Medow, M. S. (2017). Nitric oxide synthase inhibition restores orthostatic tolerance in young vasovagal syncope patients. Heart, heartjnl-2017. Guidelines recommend β-blockers and renin-angiotensin-aldosterone system blockers to improve long-term survival in hemodynamically stable myocardial infarction patients with a reduced left ventricular ejection fraction. The prevalence and outcomes associated with β and renin-angiotensin-aldosterone system blocker therapy in patients with ongoing cardiogenic shock is unknown. van Diepen, S., Reynolds, H. R., Stebbins, A., Lopes, R. D., Džavík, V., Ruzyllo, W., ... & Dauerman, H. L. (2014). Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock. Critical care medicine, 42(2), 281-288.